Published 2009 | Version v1
Publication

Neuropeptide S selectively inhibits the release of serotonin and noradrenaline from mouse frontal cortex nerve endings

Description

Background and purpose: Neuropeptide S (NPS) is a recently identified neurotransmitter/neuromodulator able to increase arousal and wakefulness while decreasing anxiety-like behaviour. As several classical transmitters play a role in arousal and anxiety, we here investigated the possible presynaptic regulation of transmitter release by NPS. Experimental approach: Synaptosomes purified from mouse frontal cortex were prelabelled with [3H]5-hydroxytryptamine(5-HT), noradrenaline, dopamine, choline, D-aspartate or GABA and depolarized in superfusion with 12–15 mmol•L-1 KCl to evoke [3H]neurotransmitter exocytosis. NPS was added at different concentrations (0.001 to 100 nmol•L-1). Key results: NPS behaved as an extremely potent inhibitor of the evoked overflow of [3H]5-HT and [3H]noradrenaline exhibiting EC50 values in the low picomolar range. The inhibitory action of NPS on [3H]5-HT release was mimicked by [Ala2]NPS that was, however, about 100-fold less potent than the natural peptide. NPS (up to 100 nmol•L-1) was unable to affect thedepolarization-evoked overflow of [3H]D-aspartate and [3H]GABA. The neuropeptide only weakly reduced the overflow of [3H]dopamine and [3H]ACh when added at relatively high concentrations. Conclusions and implications: NPS, at low picomolar concentrations, can selectively inhibit the evoked release of 5-HT and noradrenaline in the frontal cortex by acting directly on 5-hydroxytryptaminergic and noradrenergic nerve terminals. These direct effects may explain only in part the unique behavioural activities of NPS, while an indirect involvement of other transmitters, especially of glutamate, must be considered.

Additional details

Created:
March 31, 2023
Modified:
November 29, 2023